Objective
Peripheral arterial disease (PAD) is a significant age-related medical condition with limited pharmacologic options. Severe PAD, termed critical limb ischemia (CLI), can lead to amputation. Skeletal muscle is the end organ most affected by PAD leading to ischemic myopathy and patient debility. Currently, there are not any therapeutics to treat ischemic myopathy, and proposed biologic agents have not been optimized due to a lack of pre-clinical models of PAD. Since a large animal model of ischemic myopathy may be useful in defining the optimal dosing and delivery regimens, the objective was to create and characterize a swine model of ischemic myopathy that mimics patients with severe PAD.
Methods
Yorkshire swine (N = 8) underwent acute right hindlimb ischemia via endovascular occlusion of the external iliac artery. The effect of ischemia on limb function, perfusion, and the degree of ischemic myopathy was quantified by weekly gait analysis, arteriography, hindlimb blood pressures, femoral artery duplex ultrasounds, and histologic examination. Animals were terminated at 5 (N = 5) and 6 (N = 3) weeks post-operatively. Ossabaw swine (N = 8) fed a high fat diet were utilized as a model of metabolic syndrome for comparison of arteriogenic recovery and validation of ischemic myopathy.
Results
There was persistent ischemia in the right hindlimb and occlusion pressures were significantly depressed compared to the untreated left hindlimb out to 6 weeks (SBP 31±21 versus 83±15, respectively; P=0.0007). The blood pressure reduction resulted in a significant increase of ischemic myopathy in the gastrocnemius muscle in the treated limb. Gait analysis revealed a functional deficit of the right hindlimb immediately post-occlusion that improved rapidly over the first 2 weeks. Peak systolic velocity values in the right common femoral artery were severely diminished throughout the entire study (P<0.001), and the hemodynamic environment post-occlusion was characterized by low and oscillatory wall shear stress. Finally, the internal iliac artery on the side of the ischemic limb underwent significant arteriogenic remodeling (1.8x baseline) in the Yorkshire, but not the Ossabaw swine model.
Conclusions
This model utilizes endovascular technology to produce the first durable large animal model of ischemic myopathy. Acutely (first 2 weeks) this model is associated with impaired gait but no tissue loss. Chronically (2-6 weeks), this model delivers persistent ischemia resulting in ischemic myopathy similar to that seen in PAD patients. This model may be of use for testing novel therapeutics including biologic therapies for promoting neovascularization and arteriogenesis.